Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era
Aims Fibrosis‐4 index (FIB‐4) and non‐alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) are the two most widely used non‐invasive tools for screening of advanced fibrosis in subjects with NAFLD. Since metabolic dysfunction‐associated fatty liver disease (MAFLD) has been proposed as a new ca...
Gespeichert in:
| Veröffentlicht in: | Hepatology research 2022-03, Vol.52 (3), p.247-254 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 254 |
|---|---|
| container_issue | 3 |
| container_start_page | 247 |
| container_title | Hepatology research |
| container_volume | 52 |
| creator | Park, Huiyul Yoon, Eileen L. Kim, Mimi Lee, Jonghyun Kim, Jung‐Hwan Cho, Seon Jun, Dae Won Nah, Eun‐Hee |
| description | Aims
Fibrosis‐4 index (FIB‐4) and non‐alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) are the two most widely used non‐invasive tools for screening of advanced fibrosis in subjects with NAFLD. Since metabolic dysfunction‐associated fatty liver disease (MAFLD) has been proposed as a new category of fatty liver disease, we aimed to compare the diagnostic performance of FIB‐4 and NFS in subjects with MAFLD and in various subgroups.
Methods
This study was designed as cross‐sectional study. Data from 6775 subjects who underwent magnetic resonance elastography (MRE) and abdominal ultrasonography at the same time during a health check‐up at 13 various health check‐up centers were retrospectively reviewed. Advanced fibrosis was defined as an MRE value of ≥3.6 kPa.
Results
The area under the receiver operating characteristic curves (AUROCs) of FIB‐4 and NFS for diagnosing advanced fibrosis were similar in subjects with MAFLD. However, the AUROC of NFS was lower than that of FIB‐4 in the diabetic subgroup of MAFLD (0.809 in FIB‐4 vs. 0.717 in NFS, p = 0.002). The performances of both FIB‐4 and NFS were poor in the subgroup of MAFLD with significant alcohol intake.
Conclusions
The overall diagnostic performance of FIB‐4 and NFS for diagnosing advanced fibrosis did not differ among subjects with MAFLD. However, the performance of NFS was lower in the diabetes subgroup of MAFLD. The diagnostic performance of FIB‐4 was better for fibrosis in various subgroups of MAFLD. |
| doi_str_mv | 10.1111/hepr.13737 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2604452381</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2604452381</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4477-c33d6d3233ad238ab49f05017fc2d2833bae2480bec1bad4092344b593b50cb53</originalsourceid><addsrcrecordid>eNp9kctKHUEQhhuJqDFufIDQkE0IjOnu6rktk4MnCqIhF8hu6EtN0jLTPXbPiZydj-Az-iT28ZgsskhtqqA-Por6CTnm7ITnev8Lp3jCoYZ6hxzwphYFA_njRZ6hqYoKZLVPXqZ0zRivmZB7ZB9kI3kF4oD4RRgnFV0KnoaeWqd--pBmZ-iEsQ9xVN4g1TjfInq6PP_4cHcvqfKWXi6_UufpiLPSYXAmL1RKwTg1o6W9muc1HdxvjFmaUCWkGNUrsturIeHRcz8k35en3xZnxcXVp_PFh4vCSFnXhQGwlQUBoKyARmnZ9qzM5_dGWNEAaIVCNkyj4VpZyVoBUuqyBV0yo0s4JG-33imGmxWmuRtdMjgMymNYpU5UTMoyq3lG3_yDXodV9Pm6TIEUbVuLjfDdljIxpBSx76boRhXXHWfdJoVuk0L3lEKGXz8rV3pE-xf98_YM8C1w6wZc_0fVnZ1-_rKVPgI4bpOT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2634299725</pqid></control><display><type>article</type><title>Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era</title><source>Wiley Online Library Journals Frontfile Complete</source><creator>Park, Huiyul ; Yoon, Eileen L. ; Kim, Mimi ; Lee, Jonghyun ; Kim, Jung‐Hwan ; Cho, Seon ; Jun, Dae Won ; Nah, Eun‐Hee</creator><creatorcontrib>Park, Huiyul ; Yoon, Eileen L. ; Kim, Mimi ; Lee, Jonghyun ; Kim, Jung‐Hwan ; Cho, Seon ; Jun, Dae Won ; Nah, Eun‐Hee</creatorcontrib><description>Aims
Fibrosis‐4 index (FIB‐4) and non‐alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) are the two most widely used non‐invasive tools for screening of advanced fibrosis in subjects with NAFLD. Since metabolic dysfunction‐associated fatty liver disease (MAFLD) has been proposed as a new category of fatty liver disease, we aimed to compare the diagnostic performance of FIB‐4 and NFS in subjects with MAFLD and in various subgroups.
Methods
This study was designed as cross‐sectional study. Data from 6775 subjects who underwent magnetic resonance elastography (MRE) and abdominal ultrasonography at the same time during a health check‐up at 13 various health check‐up centers were retrospectively reviewed. Advanced fibrosis was defined as an MRE value of ≥3.6 kPa.
Results
The area under the receiver operating characteristic curves (AUROCs) of FIB‐4 and NFS for diagnosing advanced fibrosis were similar in subjects with MAFLD. However, the AUROC of NFS was lower than that of FIB‐4 in the diabetic subgroup of MAFLD (0.809 in FIB‐4 vs. 0.717 in NFS, p = 0.002). The performances of both FIB‐4 and NFS were poor in the subgroup of MAFLD with significant alcohol intake.
Conclusions
The overall diagnostic performance of FIB‐4 and NFS for diagnosing advanced fibrosis did not differ among subjects with MAFLD. However, the performance of NFS was lower in the diabetes subgroup of MAFLD. The diagnostic performance of FIB‐4 was better for fibrosis in various subgroups of MAFLD.</description><identifier>ISSN: 1386-6346</identifier><identifier>EISSN: 1872-034X</identifier><identifier>DOI: 10.1111/hepr.13737</identifier><identifier>PMID: 34841632</identifier><language>eng</language><publisher>Netherlands: Wiley Subscription Services, Inc</publisher><subject>Diabetes mellitus ; Fatty liver ; Fibrosis ; fibrosis‐4 index ; hepatic fibrosis ; Liver diseases ; magnetic resonance elastography ; metabolic dysfunction‐associated fatty liver ; Metabolism ; non‐alcoholic fatty liver disease fibrosis score</subject><ispartof>Hepatology research, 2022-03, Vol.52 (3), p.247-254</ispartof><rights>2021 Japan Society of Hepatology.</rights><rights>2022 The Japan Society of Hepatology.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4477-c33d6d3233ad238ab49f05017fc2d2833bae2480bec1bad4092344b593b50cb53</citedby><cites>FETCH-LOGICAL-c4477-c33d6d3233ad238ab49f05017fc2d2833bae2480bec1bad4092344b593b50cb53</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fhepr.13737$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fhepr.13737$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34841632$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Park, Huiyul</creatorcontrib><creatorcontrib>Yoon, Eileen L.</creatorcontrib><creatorcontrib>Kim, Mimi</creatorcontrib><creatorcontrib>Lee, Jonghyun</creatorcontrib><creatorcontrib>Kim, Jung‐Hwan</creatorcontrib><creatorcontrib>Cho, Seon</creatorcontrib><creatorcontrib>Jun, Dae Won</creatorcontrib><creatorcontrib>Nah, Eun‐Hee</creatorcontrib><title>Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era</title><title>Hepatology research</title><addtitle>Hepatol Res</addtitle><description>Aims
Fibrosis‐4 index (FIB‐4) and non‐alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) are the two most widely used non‐invasive tools for screening of advanced fibrosis in subjects with NAFLD. Since metabolic dysfunction‐associated fatty liver disease (MAFLD) has been proposed as a new category of fatty liver disease, we aimed to compare the diagnostic performance of FIB‐4 and NFS in subjects with MAFLD and in various subgroups.
Methods
This study was designed as cross‐sectional study. Data from 6775 subjects who underwent magnetic resonance elastography (MRE) and abdominal ultrasonography at the same time during a health check‐up at 13 various health check‐up centers were retrospectively reviewed. Advanced fibrosis was defined as an MRE value of ≥3.6 kPa.
Results
The area under the receiver operating characteristic curves (AUROCs) of FIB‐4 and NFS for diagnosing advanced fibrosis were similar in subjects with MAFLD. However, the AUROC of NFS was lower than that of FIB‐4 in the diabetic subgroup of MAFLD (0.809 in FIB‐4 vs. 0.717 in NFS, p = 0.002). The performances of both FIB‐4 and NFS were poor in the subgroup of MAFLD with significant alcohol intake.
Conclusions
The overall diagnostic performance of FIB‐4 and NFS for diagnosing advanced fibrosis did not differ among subjects with MAFLD. However, the performance of NFS was lower in the diabetes subgroup of MAFLD. The diagnostic performance of FIB‐4 was better for fibrosis in various subgroups of MAFLD.</description><subject>Diabetes mellitus</subject><subject>Fatty liver</subject><subject>Fibrosis</subject><subject>fibrosis‐4 index</subject><subject>hepatic fibrosis</subject><subject>Liver diseases</subject><subject>magnetic resonance elastography</subject><subject>metabolic dysfunction‐associated fatty liver</subject><subject>Metabolism</subject><subject>non‐alcoholic fatty liver disease fibrosis score</subject><issn>1386-6346</issn><issn>1872-034X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><recordid>eNp9kctKHUEQhhuJqDFufIDQkE0IjOnu6rktk4MnCqIhF8hu6EtN0jLTPXbPiZydj-Az-iT28ZgsskhtqqA-Por6CTnm7ITnev8Lp3jCoYZ6hxzwphYFA_njRZ6hqYoKZLVPXqZ0zRivmZB7ZB9kI3kF4oD4RRgnFV0KnoaeWqd--pBmZ-iEsQ9xVN4g1TjfInq6PP_4cHcvqfKWXi6_UufpiLPSYXAmL1RKwTg1o6W9muc1HdxvjFmaUCWkGNUrsturIeHRcz8k35en3xZnxcXVp_PFh4vCSFnXhQGwlQUBoKyARmnZ9qzM5_dGWNEAaIVCNkyj4VpZyVoBUuqyBV0yo0s4JG-33imGmxWmuRtdMjgMymNYpU5UTMoyq3lG3_yDXodV9Pm6TIEUbVuLjfDdljIxpBSx76boRhXXHWfdJoVuk0L3lEKGXz8rV3pE-xf98_YM8C1w6wZc_0fVnZ1-_rKVPgI4bpOT</recordid><startdate>202203</startdate><enddate>202203</enddate><creator>Park, Huiyul</creator><creator>Yoon, Eileen L.</creator><creator>Kim, Mimi</creator><creator>Lee, Jonghyun</creator><creator>Kim, Jung‐Hwan</creator><creator>Cho, Seon</creator><creator>Jun, Dae Won</creator><creator>Nah, Eun‐Hee</creator><general>Wiley Subscription Services, Inc</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7U9</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>202203</creationdate><title>Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era</title><author>Park, Huiyul ; Yoon, Eileen L. ; Kim, Mimi ; Lee, Jonghyun ; Kim, Jung‐Hwan ; Cho, Seon ; Jun, Dae Won ; Nah, Eun‐Hee</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4477-c33d6d3233ad238ab49f05017fc2d2833bae2480bec1bad4092344b593b50cb53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Diabetes mellitus</topic><topic>Fatty liver</topic><topic>Fibrosis</topic><topic>fibrosis‐4 index</topic><topic>hepatic fibrosis</topic><topic>Liver diseases</topic><topic>magnetic resonance elastography</topic><topic>metabolic dysfunction‐associated fatty liver</topic><topic>Metabolism</topic><topic>non‐alcoholic fatty liver disease fibrosis score</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Park, Huiyul</creatorcontrib><creatorcontrib>Yoon, Eileen L.</creatorcontrib><creatorcontrib>Kim, Mimi</creatorcontrib><creatorcontrib>Lee, Jonghyun</creatorcontrib><creatorcontrib>Kim, Jung‐Hwan</creatorcontrib><creatorcontrib>Cho, Seon</creatorcontrib><creatorcontrib>Jun, Dae Won</creatorcontrib><creatorcontrib>Nah, Eun‐Hee</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Hepatology research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Park, Huiyul</au><au>Yoon, Eileen L.</au><au>Kim, Mimi</au><au>Lee, Jonghyun</au><au>Kim, Jung‐Hwan</au><au>Cho, Seon</au><au>Jun, Dae Won</au><au>Nah, Eun‐Hee</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era</atitle><jtitle>Hepatology research</jtitle><addtitle>Hepatol Res</addtitle><date>2022-03</date><risdate>2022</risdate><volume>52</volume><issue>3</issue><spage>247</spage><epage>254</epage><pages>247-254</pages><issn>1386-6346</issn><eissn>1872-034X</eissn><abstract>Aims
Fibrosis‐4 index (FIB‐4) and non‐alcoholic fatty liver disease (NAFLD) fibrosis score (NFS) are the two most widely used non‐invasive tools for screening of advanced fibrosis in subjects with NAFLD. Since metabolic dysfunction‐associated fatty liver disease (MAFLD) has been proposed as a new category of fatty liver disease, we aimed to compare the diagnostic performance of FIB‐4 and NFS in subjects with MAFLD and in various subgroups.
Methods
This study was designed as cross‐sectional study. Data from 6775 subjects who underwent magnetic resonance elastography (MRE) and abdominal ultrasonography at the same time during a health check‐up at 13 various health check‐up centers were retrospectively reviewed. Advanced fibrosis was defined as an MRE value of ≥3.6 kPa.
Results
The area under the receiver operating characteristic curves (AUROCs) of FIB‐4 and NFS for diagnosing advanced fibrosis were similar in subjects with MAFLD. However, the AUROC of NFS was lower than that of FIB‐4 in the diabetic subgroup of MAFLD (0.809 in FIB‐4 vs. 0.717 in NFS, p = 0.002). The performances of both FIB‐4 and NFS were poor in the subgroup of MAFLD with significant alcohol intake.
Conclusions
The overall diagnostic performance of FIB‐4 and NFS for diagnosing advanced fibrosis did not differ among subjects with MAFLD. However, the performance of NFS was lower in the diabetes subgroup of MAFLD. The diagnostic performance of FIB‐4 was better for fibrosis in various subgroups of MAFLD.</abstract><cop>Netherlands</cop><pub>Wiley Subscription Services, Inc</pub><pmid>34841632</pmid><doi>10.1111/hepr.13737</doi><tpages>8</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1386-6346 |
| ispartof | Hepatology research, 2022-03, Vol.52 (3), p.247-254 |
| issn | 1386-6346 1872-034X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2604452381 |
| source | Wiley Online Library Journals Frontfile Complete |
| subjects | Diabetes mellitus Fatty liver Fibrosis fibrosis‐4 index hepatic fibrosis Liver diseases magnetic resonance elastography metabolic dysfunction‐associated fatty liver Metabolism non‐alcoholic fatty liver disease fibrosis score |
| title | Comparison of diagnostic performance between FIB‐4 and NFS in metabolic‐associated fatty liver disease era |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-02T08%3A01%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20diagnostic%20performance%20between%20FIB%E2%80%904%20and%20NFS%20in%20metabolic%E2%80%90associated%20fatty%20liver%20disease%20era&rft.jtitle=Hepatology%20research&rft.au=Park,%20Huiyul&rft.date=2022-03&rft.volume=52&rft.issue=3&rft.spage=247&rft.epage=254&rft.pages=247-254&rft.issn=1386-6346&rft.eissn=1872-034X&rft_id=info:doi/10.1111/hepr.13737&rft_dat=%3Cproquest_cross%3E2604452381%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2634299725&rft_id=info:pmid/34841632&rfr_iscdi=true |